Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc reports results for the quarter ended in June - Earnings Summary

* Abcellera Biologics Inc  ABCL.OQ  reported a quarterly
adjusted
loss of 2 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 2 cents per share.
    * Revenue rose 66.1% to $45.92 million from a year ago;
analysts
expected $53.59 million. 
    * Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 2 cents​.
    * The mean earnings estimate of analysts had fallen by
about 133.4% in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * Abcellera Biologics Inc shares had risen by 10.4% this
quarter and lost 17.8% so far this year.
    * The company reported a quarterly loss of $6.79 million.
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 03:47 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.02          -0.02          Met
 Mar. 31 2022      0.38           0.54           Beat
 Dec. 31 2021      0.19           0.19           Met
 Sep. 30 2021      -0.05          -0.08          Missed

Recent news on AbCellera Biologics

See all news